Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15611MR)

This product GTTS-WQ15611MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF13C gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_052945.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 115650
UniProt ID Q96RJ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15611MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2740MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ14777MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ12644MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ14074MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ15832MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ3190MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ2946MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ2315MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN6000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW